This article has Open Peer Review reports available.
The science of clinical practice: disease diagnosis or patient prognosis? Evidence about “what is likely to happen” should shape clinical practice
- Peter Croft1Email author,
- Douglas G Altman2,
- Jonathan J Deeks3,
- Kate M Dunn1,
- Alastair D Hay4,
- Harry Hemingway5,
- Linda LeResche6,
- George Peat1,
- Pablo Perel7,
- Steffen E Petersen8,
- Richard D Riley1, 9,
- Ian Roberts7,
- Michael Sharpe10,
- Richard J Stevens11,
- Danielle A Van Der Windt1,
- Michael Von Korff12 and
- Adam Timmis13
© Croft et al.; licensee BioMed Central. 2015
Received: 19 September 2014
Accepted: 24 December 2014
Published: 30 January 2015
Diagnosis is the traditional basis for decision-making in clinical practice. Evidence is often lacking about future benefits and harms of these decisions for patients diagnosed with and without disease. We propose that a model of clinical practice focused on patient prognosis and predicting the likelihood of future outcomes may be more useful.
Disease diagnosis can provide crucial information for clinical decisions that influence outcome in serious acute illness. However, the central role of diagnosis in clinical practice is challenged by evidence that it does not always benefit patients and that factors other than disease are important in determining patient outcome. The concept of disease as a dichotomous ‘yes’ or ‘no’ is challenged by the frequent use of diagnostic indicators with continuous distributions, such as blood sugar, which are better understood as contributing information about the probability of a patient’s future outcome. Moreover, many illnesses, such as chronic fatigue, cannot usefully be labelled from a disease-diagnosis perspective. In such cases, a prognostic model provides an alternative framework for clinical practice that extends beyond disease and diagnosis and incorporates a wide range of information to predict future patient outcomes and to guide decisions to improve them. Such information embraces non-disease factors and genetic and other biomarkers which influence outcome.
Patient prognosis can provide the framework for modern clinical practice to integrate information from the expanding biological, social, and clinical database for more effective and efficient care.
The traditional model of clinical practice incorporates diagnosis, prognosis, and treatment . Diagnosis classifies the sick patient as having or not having a particular disease. Historically, diagnosis was regarded as the primary guide to treatment and prognosis (“what is likely to happen in the future”), and is still considered the core component of clinical practice .
This traditional model now has to meet the demand for health care to deliver demonstrable quality. Changes in clinical practice must be justified by better outcomes, as valued by patients, or more efficient and safer delivery of health care. The usefulness of diagnostic and treatment decisions, and the value of new tests and interventions, are judged by whether patients classified with diagnosed disease do better and those classified without disease come to no harm .
This requires information about patient prognosis – the likelihood of future outcomes in patients with a given disease or health condition. Prognosis research aims to understand the likelihood of different outcomes, which factors predict these likelihoods, how best to estimate an individual’s likelihood of different outcomes, and how this information can be used to target interventions and improve outcomes .
Importantly, patient prognosis is influenced by more than disease diagnosis and diagnosis-driven treatment. Among women with advanced breast cancer, for example, treatment responsiveness and toxicity as well as survival are informed by their physical wellbeing and appetite prior to the start of treatment . The multiplicity of biological, clinical, and social factors that inform the likelihood of an individual’s future outcome challenges the idea that prognosis and treatment selection are exclusively determined by diagnosis. Guidelines on statin use, for example, have shifted from “treat hypercholesterolaemia” to “treat the risk of adverse cardiovascular outcomes”, emphasising the continuous and multifactorial nature of risk for adverse outcomes that might be lowered by intervention [6,7].
In this paper, we consider the case for prognosis to replace diagnosis as the framework for clinical decision-making. For some patients, especially those with acute illness or injury, a prognosis-based model will be dominated by diagnostic disease-based information. For many others, notably patients with long-term ill-health, healthy people classified as having a risk-based condition, and persons in screening programmes, a model framed by prognosis would integrate diagnostic and treatment information with other data relevant to future health, and place evidence about the probability of future outcomes, and how to improve those outcomes, at the forefront of clinical thinking and decision-making. Such a model has the potential to reduce or avoid overdiagnosis [8,9] and to promote incorporation of quantitative estimates of future outcomes into shared decision-making with patients in clinical practice . We also discuss potential downsides and limitations of a shift to prognosis-based clinical practice.
A useful diagnosis is defined by patient prognosis
Diagnosis classifies sick people into groups defined by disease and pathology . The frameworks to explain illness have expanded from pathoanatomical to physiological-biochemical-psychological and, more recently, genetic-molecular models, but the basic concept of diagnosis has not changed. Diagnosis provides clinicians with the means to organise and interpret a range of information provided by patient symptoms, signs, tests, and investigations as the basis for decision-making.
Example: The primary care physician faced with the common clinical problem of a child with fever is concerned not to miss rare but serious diagnoses needing specific treatments. A correct diagnosis of meningococcal meningitis will dictate life-saving, targeted antibiotic treatment. Also, correctly classifying the majority of children with fever who have self-limiting infections will underpin appropriate reassurance, and avoid antimicrobial therapy and potentially harmful specialist investigations.
Diagnosis and disease mechanisms inform the decisions in this example, yet patient prognosis is the underlying concern. The concern is firstly to correctly identify the few children who, unless they receive urgent treatment targeted at a specific disease, have a high likelihood of poor outcome (disease diagnosis being a highly effective way to improve prognosis in these individuals) and, secondly, to allow the many children with fever who have a high likelihood of a good outcome to recover without disease-targeted interventions.
Example: Urinary tract infections in children present in ways which overlap with many other acute childhood illnesses. The diagnostic challenge is to identify children whose urine contains bacteria so that antibiotic therapy can be rationalised and kept to a safe minimum. Carrying out high quality microbiology on urine samples from all acutely unwell children is difficult and inefficient. Research seeks clinical prediction rules that select children with an increased probability of bacteriologically-positive infection for urine testing , using information including sociodemographics and urinary and non-urinary symptoms. The question is whether application of the prediction rule, plus targeted testing and treatment of identified bacteriologically-positive children, improves outcomes for those who are tested and does no harm to those who are not.
This example illustrates how a stratified process for diagnosis may support clinical decisions, including avoiding unnecessary investigation and treatment in patients with low disease probability. The usefulness of this process is defined by the prognosis of all children engaged in it.
Example: A new source of information about suspected coronary heart disease is cardiovascular magnetic resonance imaging. Medical imaging is the fastest growing physician-ordered service in the US Medicare system . The most important indicator for cardiovascular imaging in Europe is suspected coronary artery disease and myocardial ischaemia . The safety of cardiovascular imaging and its potential to change the diagnosis are established, but whether its use improves patient outcomes has not been addressed, although trials are underway . Evidence is needed since “…as an imaging community we have failed to demonstrate the added value of cardiac imaging in terms of improved quality of care or improved outcomes” .
This demand for prognostic evidence of improved outcomes when evaluating new diagnostic information poses substantial challenges of feasibility for the necessary research, especially for studies of long-term impact and cost; this is a limitation on the prognostic model. Information science, and its expanding reservoir of data linked to patient outcomes, will need to drive novel methods to address these questions such as modelling of long-term outcomes by combining data from cross-sectional diagnostic and short-term effectiveness studies.
Prognosis identifies overdiagnosis
In all three examples above, the usefulness of diagnosis is defined by evidence about patient prognosis, but the clinical process remains focused on disease. The assumption is that identifying individuals with disease optimises their outcome. This assumption may not always be justified.
Example: A patient presenting with mild urinary symptoms has prostate cancer diagnosed by a test and histopathology. The grading of his cancer places him at one end of the spectrum of risk of future poor outcome, with a low probability that he will die prematurely and evidence that surgical treatment would not alter this probability . Furthermore, if surgically treated, there is a risk of undesirable outcomes such as reduced genito-urinary function. The evidence base to inform clinical, personal, and policy decisions needs to show how use of diagnostic tests to identify and classify prostate cancer links to outcomes with and without treatment [8,9], i.e., decisions should be informed by evidence about patient prognosis. We cannot assume the pursuit of diagnosis and disease is beneficial in the absence of evidence about future outcomes.
Overdiagnosis flourishes in the vacuum created by a culture of ‘underprognosis’, i.e., lack of critical enquiry, information, or evidence about the likely future benefits or harms of identifying a condition as an abnormal disease state. A prognostic framework for clinical practice would help to resist evidence-free diagnostic novelty. Prognostic evidence highlights when overenthusiastic search for pathology leads to irrelevant treatments and needless anxiety, such as disc anomalies on MRI of the spine , but can reassure people who need neither active intervention nor a diagnosis, and identify those in whom diagnosis does guide decisions that improve outcomes.
Concerns about overdiagnosis are often generated by screening programmes which diagnose early or latent disease in healthy people. There is debate, for example, about how much breast cancer screening programmes reduce premature mortality, and to what extent the nature and rate of adverse consequences are acceptable, i.e., how population prognosis changes as a result of a screening programme . Overdiagnosis of lesions that do not confer poor prognosis or affect future outcomes is an important adverse consequence of breast cancer screening because of the implications of unnecessary anxiety, investigation, and treatment in patients with such lesions.
Patient prognosis is determined by more than disease diagnosis
Example: A physician, working during a typhoid outbreak in the UK in the 1930’s, provided care for the many who recovered and the few who did not . He wrote “A patient with typhoid fever usually inclines to recovery: it is a natural proclivity in one with the disease”. Diagnosis characterised the sick group but was less important to the people involved than knowledge that most were likely to get better.
Example: The potential benefit of early diagnosis of type 2 diabetes was investigated in persons identified from primary care records as being at risk of the condition . Outcomes were compared between groups invited and not invited for diabetes screening. Management of persons diagnosed with diabetes in the screened group focused on improving prognosis by attempting to reduce their risk of future cardiovascular disease, targeting blood pressure, and cholesterol as well as blood glucose. Ten-year mortality was similar in the screened and unscreened groups. One explanation for this finding was that systematic cardiovascular risk factor management in the screened population was only offered to persons diagnosed with diabetes rather than to everyone invited for screening.
Example: Although a person with multiple diseases will benefit from optimal care for each separate condition by disease-based specialists, the multimorbidity state itself contributes to poor prognosis, for example a higher probability of unplanned hospitalisation, and outcomes are improved if there is additional integrated care from generalists . However, much multimorbidity concerns risk-based measures (blood sugar, kidney function, blood pressure), which are more usefully considered as continuous variables rather than disease states . In constructing prognostic models to support decision-making for people with multimorbidity, such biological measures can be integrated with subjective measures, such as mood state, pain severity, and mobility limitation, to create quantitative estimates of prognosis to inform care for people with multiple long-term conditions.
Traditional disease-based classification systems are being challenged by the quest for new ways to classify persons with multimorbidity and to incorporate new information about health, such as genomics, into such systems . This new information is undermining the idea that medicine only starts when there is a diagnostic label. Biomedical diagnoses have also traditionally encouraged isolated disease-based measures of outcome, such as normal blood glucose, to assess the success of health care. The acceptance that patient-focused measures, such as improved or maintained social participation, are realistic and desirable outcomes of health care for patients with long-term conditions  is subverting the idea that good prognosis is only judged by disease cure.
Not “have you got it or not?” but “how much have you got?”
Clinical decisions are often dichotomous (does this person have something serious or not? should this patient be allowed to drive or not?). Diagnosis as “either you have it or you don’t” (is it a heart attack or not?) aligns with such yes/no decisions, but the diagnostic process itself is often more probabilistic and uncertain – a series of decisions, guided at each stage by the changed probability of a diagnosis being present or not and designed to gradually reduce uncertainty . However, this process still assumes there is an underlying dichotomous disease state (yes or no); this assumption may be flawed.
The underlying ‘disease’ is often a continuous distribution of probability for future health states. Diagnosis is then not “have you got it?” but “how much of it have you got?” Gale , for example, has argued that there is no single pathology underlying diabetes, and that its identification and diagnosis subsumes much heterogeneity, given blood glucose is a continuously distributed variable. Vickers et al.  highlight that many such risk variables are artificially dichotomised and treated as disease states rather than as sources of information about probability of future events, which provide a quantitative estimate of individual risk for particular outcomes.
It can be argued that diagnosis does incorporate variability under the concept of disease severity. The continuous distribution of blood pressure, for example, aligns with severity of the ‘disease’ (or unhealthy state). The diagnostic paradigm, however, focuses on classification and misclassification of ‘hypertension’. The prognostic approach more naturally accommodates the idea of severity by relating increasing levels of blood pressure to contrasting outcomes.
A potential downside of the prognostic approach is whether clinical models in the real world can incorporate the continuous nature and variability of risk of future avoidable outcomes into decision making. Calculation of prognostic likelihoods and treatment responsiveness can combine all relevant information, but validation and translation of prognostic models into practice often relies still on categorisation (high-medium-low risk of a particular outcome) to drive stratified care [28,29]. Evidence about the clinical usefulness of such new categorisations is essential – prognostic classification for its own sake should not replace diagnosis for its own sake . Nor should individual patient prognosis be a static classification in time – it needs to be updated with recent predictor values, or a profile of values over time, to reflect how clinical practice works in the real world by using new information and repeat consultations to modify treatment.
There are practical challenges to introducing an information-rich prognosis framework for a real-world clinical practice already struggling with volumes of guidelines, decision-aids, and protocols of care. Technological and statistical advances to make calculation and presentation of prognostic information more accessible and research into ways in which health care professionals and patients can better assimilate, use, and share prognostic information could help to meet these challenges.
The pros and cons of labelling people
Diagnosis and disease do not represent unchanging truth. Historians and sociologists have described how apparently robust diagnostic entities, such as coronary heart disease, conceal a history of shifting boundaries and definitions [10,31,32]. These shifts reflect not only scientific advance and expanding knowledge (e.g., the identification of Helicobacter as a cause of peptic ulcer), but also the recurring need to organise medical knowledge in practical and pragmatic ways to aid clinical and public health decision-making. However, it is equally clear that such shifts are taken up, shaped, and driven by professional ambition, pharmaceutical industry interests, and the commercial drive for profit, and that they influence and are influenced by changing social context and cultural norms, for example, changes in mental illness classification. “Even US law now recognizes that disease is no longer a unique collection of symptoms equalling a given condition, but rather a constellation of current symptoms, previous exposures, and future potential manifestations, all of which make the art of diagnosis even more precarious” .
Example: Chronic fatigue syndrome is a ‘contested diagnosis’ . The drive for pathological explanations led to its initial characterisation in the UK as myalgic encephalomyelitis, with little evidence that such a pathological inflammatory process was responsible for the symptoms. The failure of clinical science to identify a mechanism to support the diagnosis means that patients with chronic fatigue often perceive their symptoms are not believed. The outcome of patients with symptoms of persistent fatigue, however, is of high relevance, regardless of the biomedical status of the syndrome.
Whilst biomedical science often ignores such problems, patients believe biomedicine could and should come up with the answer . Prognostic classification provides a practical way forward. Modifiable patient characteristics that contribute to poor prognosis in chronic fatigue (e.g., low activity level, depression, insomnia) provide targets for intervention in the absence of a definitive biomedical explanation. Targeted exercise programmes, for example, improve prognosis in persons at risk of persisting problems .
Diagnosis, however, has functions other than revealing pathological truth. A diagnostic label provides the patient with meaning and value for symptoms regardless of whether these have a biomedical explanation . Diagnosis legitimates the sickness state, and gives access to support and benefits . Prognostic statements may not provide the same immediate value as a diagnostic label, and some patients may be more interested in ‘have I got high cholesterol?’ than in the language of risk. A culture is needed in which clinicians and patients can work together on improving outcomes in the absence of the apparent certainty provided by a diagnostic label.
A hazard of applying a prognostic model in clinical practice relates to the very thing it is designed to reduce, namely over-medicalization of daily life. We have discussed how excessive diagnostic zeal in the absence of improved outcomes for the patient, and the wish to find a pathology to explain every symptom, and the application of diagnostic labels to asymptomatic risk factors, may all lead to ineffective and inefficient care, and harmful side-effects for the patient. The potential for a prognostic model of care to solve these problems has to be weighed against the possibility that such a model may create its own version of over-medicalization. Aronowitz points to healthy individuals locked rather fearfully into long-term surveillance of risk markers, believing this is the way to ensure continuing good prognosis, even if their risk of death and other adverse outcomes is low . The anxieties, and unnecessary and inefficient health care, and commercial and professional interests involved look remarkably similar to those associated with unevidenced diagnostic excess. The resolution lies in demanding high quality evidence of what is and is not useful for improving outcomes, i.e., pursuit of the best prognostic evidence as the scientific basis for resisting excessive medicalization.
Prognosis provides a natural framework for modern clinical practice
Example: Evidence that clinicians and patients can integrate disease-based explanation within a broader framework of prognosis is provided by back pain. Primary care practitioners undertake initial triage in a diagnostic framework to identify rare underlying conditions which have a poor immediate prognosis unless treated (e.g., cord compression from a tumour). Once these are excluded, the task diverts from diagnosis and considers the clinical problem as the risk of poor long-term outcomes (work loss, persistent pain). Activity limitation, psychological distress, and capacity to cope are used to classify people into prognostic categories that drive treatment decisions . The many at low risk of a poor outcome are managed without referral or investigation, whereas more intense care is targeted at those with poorer prognosis. This exemplifies the principle of ‘stratified care’. Use of this prognostic approach to select back pain patients for different treatment programmes was effective and cost effective in a randomised controlled trial .
Such personalised medicine is likely to herald preferential expansion of prognostic modelling of individual risk for future health outcomes over new diagnostic tests of current disease status. However, research to inform and justify a prognostic model of clinical practice is crucial, including the important uncertainties about the application of this model represented by clinical, patient, and public understanding of risk and probability.
We propose that prognosis can now provide the framework in which clinicians and researchers organise evidence and information to support decisions about management. This extends calls for a risk-centred approach to many syndromes and chronic conditions  and parallels proposals that public health should be organised around achievable outcomes rather than disease categories . Such a framework shifts the focus of clinical practice to improving outcomes for patients in their total biological, psychological, and social environment and away from an exclusive and narrow focus on underlying disease as the determinant of outcome.
Although biomedical diagnosis is often a crucial driver of treatment selection, especially in acute life-threatening illness such as infection and trauma, diagnostic labelling and subgrouping for many ill people is about providing prognostic information to support decisions about targeted individual long-term care. A broader prognostic framework could integrate such information with evidence about other pathophysiological, psychological, behavioural, and environmental factors that affect patient outcomes, to avoid overdiagnosis and support doctors and their patients in probability-based decision-making in clinical practice.
Prognosis is not a panacea for all the problems we have discussed in relation to diagnosis, and there must be continuing debate about the benefits, value, limits, harms, and costs of medicalization and medical care. However, because prognostic classification incorporates a much wider range of information than diagnosis and disease factors alone, and because such information is expanding rapidly in volume and availability , prognosis can provide a realistic, practical, and useful framework for clinical and public health practice.
This paper summarises work arising from the “Diagnosis-to-Prognosis Workshop” organised by the MRC PROGnosis RESearch Strategy (PROGRESS) Partnership www.progress-partnership.org and is supported by a Medical Research Council (UK) Partnership Grant (G0902393). PC and DGA are UK National Institute of Health Research (NIHR) Senior Investigators. PC, KMD, ADH, GP, RDR, RJS, and DA Van Der Windt and their departments are members of the NIHR School of Primary Care Research. KMD is supported by the Wellcome Trust . HH is supported by grants from the NIHR (RP-PG-0407-10314; http://www.nihr.ac.uk/), and Wellcome Trust (086091/Z/08/Z; http://www.wellcome.ac.uk/) and by awards establishing the Farr Institute of Health Informatics Research, London, from the MRC, in partnership with Arthritis Research UK, the British Heart Foundation, Cancer Research UK, the Economic and Social Research Council, the Engineering and Physical Sciences Research Council, the NIHR, the National Institute for Social Care and Health Research (Welsh Assembly Government), the Chief Scientist Office (Scottish Government Health Directorates) and the Wellcome Trust (MR/K006584/1). SEP and AT acknowledge support of Bart’s NIHR Cardiovascular Biomedical Research Unit. MS is supported by the Oxford NIHR Collaboration for Leadership in Applied Health Research and Care. The contributions of MVK and LLR were supported by National Institute on Aging grant 1R01 AG034181.
- Chauffard A. Medical prognosis: its methods, its evolution, its limitations. BMJ. 1913;2:286–90.View ArticlePubMedPubMed CentralGoogle Scholar
- Del Mar C, Doust J, Glasziou P. Clinical thinking. Oxford: Blackwell Publishing Ltd., BMJ Books; 2006.Google Scholar
- Lord SJ, Staub LP, Bossuyt PM, Irwig LM. Target practice: choosing target conditions for test accuracy studies that are relevant to clinical practice. BMJ. 2011;343:d4684.View ArticlePubMedGoogle Scholar
- Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, et al. Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ. 2013;346:e5595.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee CK, Stockler MR, Coates AS, Gebski V, Lord SJ, Simes RJ. Self-reported health-related quality of life is an independent predictor of chemotherapy benefit and toxicity in women with advanced breast cancer. Br J Cancer. 2010;102:1341–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Vickers AJ, Basch E, Kattan MW. Against diagnosis. Ann Intern Med. 2008;149:200–3.View ArticlePubMedPubMed CentralGoogle Scholar
- Krumholz HM. Target cardiovascular risk rather than cholesterol concentration. BMJ. 2013;347:f7110.View ArticlePubMedGoogle Scholar
- Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ. 2012;344:e3502.View ArticlePubMedGoogle Scholar
- Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102:605–13.View ArticlePubMedGoogle Scholar
- Rosenberg Charles E. Introduction. In: Rosenberg CE, Golden J, editors. Framing disease. New Brunswick, New Jersey: Rutgers University Press; 1992.Google Scholar
- Downing H, Thomas-Jones E, Gal M, Waldron CA, Sterne J, Hollingworth W, et al. The diagnosis of urinary tract infections in young children (DUTY): protocol for a diagnostic and prospective observational study to derive and validate a clinical algorithm for the diagnosis of UTI in children presenting to primary care with an acute illness. BMC Infect Dis. 2012;12:158.View ArticlePubMedPubMed CentralGoogle Scholar
- Bossuyt PM, Reitsma JB, Linnet K, Moons KG. Beyond diagnostic accuracy: the clinical utility of diagnostic tests. Clin Chem. 2012;58:1636–43.View ArticlePubMedGoogle Scholar
- Ferrante di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PM, Deeks JJ. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ. 2012;344:e686.View ArticlePubMedGoogle Scholar
- Smith-Bindman R, Miglioretti DL, Johnson E, Lee C, Feigelson HS, Flynn M, et al. Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996–2010. JAMA. 2012;307:2400–9.View ArticlePubMedGoogle Scholar
- Bruder O, Wagner A, Lombardi M, Schwitter J, van Rossum A, Pilz G, et al. European cardiovascular magnetic resonance (EuroCMR) registry – multinational results from 57 centers in 15 countries. J Cardiovasc Magnetic Resonance. 2013;15:9.View ArticleGoogle Scholar
- Newby DE, Williams MC, Flapan AD, Forbes JF, Hargreaves AD, Leslie SJ, et al. Role of multidetector computed tomography in the diagnosis and management of patients attending the rapid access chest pain clinic, The Scottish computed tomography of the heart (SCOT-HEART) trial: study protocol for randomized controlled trial. Trials. 2012;13:184.View ArticlePubMedPubMed CentralGoogle Scholar
- Bonow RO. Sixth Annual Mario S Verani, MD Memorial Lecture: Cardiovascular imaging – added value or added cost? J Nuclear Cardiol. 2008;15:170–7.View ArticleGoogle Scholar
- Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, et al. Individualised estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomised trial. Eur Urol. 2012;62:204–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Jarvik JG, Hollingworth W, Martin B, Emerson SS, Gray DT, Overman S, et al. Rapid magnetic resonance imaging vs radiographs for patients with low back pain: a randomised controlled trial. JAMA. 2003;289:2810–8.View ArticlePubMedGoogle Scholar
- Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778–86.View ArticleGoogle Scholar
- Watson SS. The 1936 Outbreak of Typhoid Fever at Poole, Bournemouth and Christchurch. Pardy and Son Ltd: Bournemouth; 1942.Google Scholar
- Simmons RK, Echouffo-Tcheuhgui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012;380:1741–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Katon WJ, Lin EH, Von Korff M, Ciechanowski P, Ludman EJ, Young B, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010;363:2611–20.View ArticlePubMedPubMed CentralGoogle Scholar
- World Health Organization. The international classification of diseases. http://www.who.int/classifications/icd/revision/en/
- Vestbo J, Agusti A, Wouters EF, Bakke P, Calverley PM, Celli B, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study Investigators. Should we view COPD differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med. 2014;189:1022–30.View ArticlePubMedGoogle Scholar
- Wellwood J, Johannessen S, Spiegelhalter DJ. How does computer-aided diagnosis improve the management of acute abdominal pain? Ann R Coll Surg Engl. 1992;74:40–6.PubMedPubMed CentralGoogle Scholar
- Gale EAM. Is type 2 diabetes a category error? Lancet. 2013;381:1956–7.View ArticlePubMedGoogle Scholar
- Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med. 2013;10:e1001381.View ArticlePubMedPubMed CentralGoogle Scholar
- Hingorani AD, Windt DA, Riley RD, Abrams K, Moons KG, Steyerberg EW, et al. Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ. 2013;346:e5793.View ArticlePubMedPubMed CentralGoogle Scholar
- Asch DA, Patton JP, Hershey JC. Knowing for the sake of knowing: the value of prognostic information. Med Decis Making. 1990;10:47–57.View ArticlePubMedGoogle Scholar
- Aronowitz RA. Making sense of illness. Cambridge: Cambridge University Press; 1998.Google Scholar
- Jutel Annemarie Goldstein. Putting a name to it. Baltimore, MA: Johns Hopkins University Press; 2011.Google Scholar
- Brown P, Lyson M, Jenkins T. From diagnosis to social diagnosis. Soc Sci Med. 2011;73:939–43.View ArticlePubMedGoogle Scholar
- White PD, Goldsmith KA, Johnson AL, Potts L, Walwyn R, DeCesare JC, et al. PACE trial management group. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet. 2011;377:623–36.View ArticleGoogle Scholar
- Aronowitz R. Decision making and fear in the midst of life. Lancet. 2010;375:1430–1.View ArticlePubMedGoogle Scholar
- Dinant G-J, Buntinx FF, Butler CCC. The necessary shift from diagnostic to prognostic research. BMC Fam Pract. 2007;8:53.View ArticlePubMedPubMed CentralGoogle Scholar
- Stolper E, Van de Wiel M, Van Royen P, Van Bokhoven M, Van der Weijden T, Dinant GJ. Gut feelings as a third track in general practitioners’ diagnostic reasoning. J Gen Intern Med. 2011;26:197–203.View ArticlePubMedGoogle Scholar
- Roland M, Paddison C. Better management of patients with multimorbidity. BMJ. 2013;346:f2510.View ArticlePubMedGoogle Scholar
- Von Korff M, Dunn KM. Chronic pain reconsidered. Pain. 2008;138:267–78.View ArticleGoogle Scholar
- Hill JC, Whitehurst DG, Lewis M, Bryan S, Dunn KM, Foster NE, et al. Comparison of stratified primary care management for low back pain with current best practice (STarTBack): a randomised controlled trial. Lancet. 2011;378:1560–71.View ArticlePubMedPubMed CentralGoogle Scholar
- Roberts I, Jackson R. Beyond disease burden: towards solution-oriented population health. Lancet. 2013;381:2219–21.View ArticlePubMedGoogle Scholar
- Murdoch TB, Detsky AS. The inevitable application of big data to health care. JAMA. 2010;309:1351–2.View ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.